Capital Markets Day
www.activebiotech.com/en/capital-markets-day-2020/
ACTIVE BIOTECH UPDATES ITS CLINICAL STRATEGY AND PROJECTED MILESTONES
November 24, 2020 08:00 (CET)REGULATORY
Active Biotech AB (publ) (ticker: ACTI) today announced updates of its fully owned projects tasquinimod and laquinimod, as well the project naptumomab, developed in partnership with NeoTX Therapeutics. Investors, analysts and media are invited to today’s virtual Capital Markets Day where the current status and future developments of the company’s clinical portfolio and its future strategy will be highlighted.
www.activebiotech.com/en/media/pressreleases/?id=2132436
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, helen@tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com